Abiopharma

🔍 Hoge Stephen (Executive)

Company: Moderna, Inc. (MRNA)

Report Date: 2025-08-27

Detailed Transactions and Holdings:

• Acquired 1,437 shares of Common Stock (Direct)
  Date: 2025-08-27 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,453,556.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 695 shares of Common Stock at $24.73 per share (Direct)
  Date: 2025-08-27 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,452,861.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 611 shares of Common Stock (Direct)
  Date: 2025-08-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,453,472.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 296 shares of Common Stock at $25.1 per share (Direct)
  Date: 2025-08-28 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,453,176.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-27 | Code: H | nature_of_ownership: By Valhalla, LLC | shares_owned_after: 4,116.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-27 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 151,933.00 | Footnotes: F3
• Sold 1,437 shares of Restricted Stock Units (Derivative)
  Date: 2025-08-27 | Code: M | equity_swap_involved: 0 | shares_owned_after: 14,368.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4
• Sold 611 shares of Restricted Stock Units (Derivative)
  Date: 2025-08-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,663.00 | transaction_form_type: 4 | Footnotes: F1, F1, F5, F5

Footnotes:

• F1: Restricted stock units convert into common stock on a one-for-one basis.
• F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
• F3: These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
• F4: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
• F5: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.